Novo NVO announced that its once-weekly growth hormone therapy Sogroya (somapacitan) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating children with idiopathic short stature (ISS) and persistent growth disturbance. The non-binding recommendation will now be reviewed by the European Commission to make a final decision. If approved, Sogroya would become the first and only growth hormone treatment approved for ISS in the EU, potentially expanding Novo's presence in the pediatric growth disorder market.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。